Polypharmacy, Regimen Complexity, and Pharmacologic Burden

Definition and scope

Distinct measures of concurrent medication count, administration complexity, and pharmacologic burden, each requiring a specified drug universe, overlap period, scoring system, and observation source. The target population, use, and analysis remain protocol decisions; this card explains the choices and their consequences rather than approving a study.

Operational specification

Define ingredient versus product counting, prescription and nonprescription inclusion, combination products, therapeutic duplication, concurrent-coverage rule, observation window, and inpatient supply. For a regimen-complexity or anticholinergic/sedative burden score, specify the exact index/version, component weights, dose assumptions, and validation context. Medication count is not the Medication Regimen Complexity Index.

Analysis and diagnostics

Build reconciled exposure episodes before counting concurrency; separate long-term medication burden from short acute courses and supply gaps. For weighted indices, preserve a source-backed lookup and explain missing dose or administration instructions. In outcome studies, address disease severity, frailty, and indication rather than interpreting a burden score as a randomized exposure.

When NOT to use and common errors

Do not sum dispensing rows as medication count, double count ingredients in combinations, treat missing nonprescription drugs as absent, substitute one burden scale for another, or label a high count as inappropriate prescribing without clinical context.

Worked example and implementation boundary

A synthetic reconciliation has five product entries, with one duplicate entry and one product containing two unique ingredients. Under an ingredient-count convention, calculate the distinct count assuming no other overlap. The stated ingredient-count convention yields five. This is not an MRCI or anticholinergic-burden score. The code performs that explicitly stated calculation with synthetic inputs. It is not a complete fitted analysis and does not demonstrate the identification assumptions, estimate sampling uncertainty, or certify application in another population.

Data-source and reporting requirements

Preserve the provenance, dates, units, and observation rule for each input. Claims capture services and transactions under observable benefits; absence of a record is not proof that an event or resource use did not occur. EHR and registry measurements depend on the collection process and may miss care outside the system. Linked sources add reconciliation and selection questions. Primary collection can improve a missing domain but still requires valid measurement and follow-up. Report which of these limitations affects the stated use, which evidence supports the chosen inputs, and what remains uncertain.

Index definitions

Worked example

Scenario

A synthetic reconciliation has five product entries, with one duplicate entry and one product containing two unique ingredients. Under an ingredient-count convention, calculate the distinct count assuming no other overlap.

Dataset

Synthetic inputs with units defined in the scenario; no patient data.

Steps

Result

The stated ingredient-count convention yields five. This is not an MRCI or anticholinergic-burden score.

Trade-offs

Code example

product_entries = 5
duplicate_entries = 1
additional_combination_ingredient = 1
result = product_entries-duplicate_entries+additional_combination_ingredient
assert abs(result - 5) < 1e-9
print(result)

product_entries <- 5
duplicate_entries <- 1
additional_combination_ingredient <- 1
result <- product_entries-duplicate_entries+additional_combination_ingredient
stopifnot(abs(result - 5) < 1e-9)
print(result)

data worked_example;
  product_entries = 5;
  duplicate_entries = 1;
  additional_combination_ingredient = 1;
  result = product_entries-duplicate_entries+additional_combination_ingredient;
  put result=;
run;

Citations

1. [1]George J, et al. Development and Validation of the Medication Regimen Complexity Index. Annals of Pharmacotherapy. 2004.
2. [2]Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. American Journal of Epidemiology. 2016;183(8):758-764.